A share price of Sage Therapeutics Inc [SAGE] is currently trading at $7.07, up 2.61%. An important factor to consider is whether the stock is rising or falling in short-term value. The SAGE shares have gain 4.74% over the last week, with a monthly amount drifted -4.85%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, RBC Capital Mkts upgraded its rating to Sector Perform on November 21, 2024, and kept the price target unchanged to $4. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $4 on October 04, 2024. TD Cowen downgraded its rating to a Hold and reduced its price target to $10 on July 30, 2024. JP Morgan downgraded its rating to Neutral for this stock on July 25, 2024, and downed its price target to $12. In a note dated May 29, 2024, Robert W. Baird initiated an Neutral rating and provided a target price of $15 on this stock.
Sage Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.62 and $13.47. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $7.07 at the most recent close of the market. An investor can expect a potential drop of -29.28% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
Trailing Twelve Months sales for Sage Therapeutics Inc [NASDAQ:SAGE] were 47.40M which represents 77.97% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -8.06%, Pretax Profit Margin comes in at -7.48%, and Net Profit Margin reading is -7.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.75, Equity is -0.69 and Total Capital is -0.91. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sage Therapeutics Inc [NASDAQ:SAGE] is 9.13. On the other hand, the Quick Ratio is 9.13, and the Cash Ratio is 0.91. Considering the valuation of this stock, the price to sales ratio is 9.34, the price to book ratio is 1.08.
Transactions by insiders
Recent insider trading involved JONAS JEFFREY M, Officer, that happened on Dec 10 ’24 when 7500.0 shares were purchased.
